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Summary
Arrhythmogenic right-ventricular dysplasia (ARVD), a
cardiomyopathy inherited as an autosomal-dominant
disease, is characterized by fibro-fatty infiltration of the
right-ventricular myocardium. Four loci for ARVD have
been mapped in the Italian population, and recently the
first locus was mapped in inhabitants of North America.
None of the genes have been identified. We have now
identified another North American family with early on-
set of ARVD and high penetrance. All of the children
with the disease haplotype had pathological or clinical
evidence of the disease at age !10 years. The family
spans five generations, having 10 living and 2 dead af-
fected individuals, with ARVD segregating as an auto-
somal-dominant disorder. Genetic linkage analysis ex-
cluded known loci, and a novel locus was identified on
chromosome 10p12-p14. A peak two-point LOD score
of 3.92 was obtained with marker D10S1664, at a re-
combination fraction of 0. Additional genotyping and
haplotype analysis identified a shared region of 10.6 cM
between marker D10S547 and D10S1653. Thus, a novel
gene responsible for ARVD resides on the short arm of
chromosome 10. This disease is intriguing, since it ini-
tiates exclusively in the right ventricle and exhibits path-
ological features of apoptosis. Chromosomal localiza-
tion of the ARVD gene is the first step in identification
of the genetic defect and the unraveling of the molecular
basis responsible for the pathogenesis of the disease.
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Introduction
Arrhythmogenic right-ventricular dysplasia (ARVD
[MIM 107970]) is a familial cardiomyopathy of the right
ventricle (RV) and is characterized by a gradual loss of
myocytes and replacement by adipose and fibrous tissue.
A striking feature is the involvement primarily of the RV,
with a normal left ventricle. The disease initiates as a
focal entity in the epicardium of the right ventricle and
progresses to the endocardium, with thinning of the wall
(Basso et al. 1996). An inflammatory infiltrate is seldom
observed, and evidence suggests that apoptosis is the
mechanism underlying the pathological process (Valente
et al. 1998). The phenotype of ARVD is highly variable,
including ventricular tachycardia, supraventricular ar-
rhythmias, right-heart failure, or asymptomatic cardio-
megaly, but all too often the first and only symptom is
sudden death (Nava et al. 1987; Fontaine et al. 1999).
The disease is extremely difficult to diagnose, and,
since there is no single diagnostic standard, consensus
criteria were developed on the basis of structural, func-
tional, and electrocardiographic manifestations (Mc-
Kenna et al. 1994). Until recently, the disease was not
well recognized as a diagnostic entity, having several
names (Uhl anomaly, arrhythmogenic RV cardiomyopa-
thy, RV outflow-tract tachycardia), and, until 1996, was
not classified as a cardiomyopathy by the World Health
Organization (WHO; WHO/ISFC Task Force 1996). In
Italy (Corrado et al. 1990) it is the most common cause
of sudden death in young people, and in the United
States, it accounts for 17% of all sudden deaths in young
people (Shen et al. 1995). Autosomal-dominant inheri-
tance has been reported in ∼30% of cases (Thiene et al.
1997). Although no gene has yet been identified, in the
Veneto Region of Italy, where this disease appears to be
particularly prevalent, four chromosomal loci have been
mapped—namely, 1q42 (Rampazzo et al. 1995), 2q32
(Rampazzo et al. 1997), 14q12 (Severini et al. 1996),
and 14q23 (Rampazzo et al. 1994). We recently iden-
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tified a fifth locus, at 3p23 (Ahmad et al. 1998), in a
North American family. In addition to improving the
understanding of a significant cause of sudden death and
heart failure, elucidation of the molecular basis of ARVD
should provide insight into (1) why the right ventricle
is the primary chamber affected and, possibly, (2) the
regulation of apoptosis. We now report another North
American family with ARVD having a high incidence of
sudden death, early disease onset, and high penetrance.
We genotyped highly informative DNA markers that
spanned the complete genome and analyzed for genetic
linkage to the markers, which localized the gene re-
sponsible for the disease to chromosome 10p12-14.
Subjects and Methods
Clinical Evaluation
Informed consent was obtained from family members
according to the guidelines of the Baylor College ofMed-
icine. Individuals were evaluated by history, physical ex-
amination, and electrocardiogram (ECG). Additional
procedures were performed when clinically indicated:
echocardiogram, RV angiogram, endomyocardial bi-
opsy, and a 24-h ambulatory ECG. Individuals were clas-
sified as affected, normal, or indeterminate. For the de-
ceased patients, diagnosis was based on history and/or
postmortem histopathological findings. Diagnosis was
based strictly on the criteria proposed by the European
Society of Cardiology and the International Society and
Federation of Cardiology (ESC/ISFC) ARVD task force
(McKenna et al. 1994). In summary, these criteria consist
of manifestations that, on the basis of global and re-
gional dysfunction, structural alterations, RV histology,
repolarization abnormalities, depolarization/conduction
abnormalities, arrhythmias, and family history, are clas-
sified as major or minor. A positive diagnosis required
two major, one major and two minor, or four minor
criteria. The phenotypical data were interpreted without
knowledge of the genotype.
DNA Extraction and Genotype Analysis
Blood samples were collected from each family mem-
ber. Genomic DNA was extracted and cell lines were
developed as described elsewhere (Durand et al. 1995).
For individuals who had died and had been autopsied,
DNA was extracted from paraffin-embedded tissue.
Samples were genotyped with microsatellite markers
from the Cooperative Human Linkage Center and the
Ge´ne´thon map. The average interval between the mark-
ers used in the genome scan was ∼10 cM. Each PCR
reaction included 1# PCR buffer, 1.5 mM MgCl2, 100
mM of each dNTP, 20 ng of DNA, 0.5 U of Taq poly-
merase (Life Technology), and 5 pmol of each primer
(sense primers fluorescently labeled by Applied Biosys-
tem and/or Life Technologies), for a total volume of 10
ml. Reaction mixtures were heated to 95C for 5 min,
followed by 30 PCR cycles; each cycle consisted of 30
s at 94C, 30 s at 55C, and 30 s at 72C; finally, 72C
for 5 min was performed on a 9600 GeneAmp PCR
system (PE Biosystems). The PCR products for each
DNA template were appropriately pooled. One microli-
ter of the pooled products was mixed with 1.0 ml of
internal size standard and 10 ml of deionized formamide
and then was denatured and analyzed by capillary elec-
trophoresis by use of an ABI 310 genetic analyzer. The
data were automatically collected and analyzed by GE-
NESCAN and GENOTYPER 2.0 software (Applied
Biosystems).
Linkage Analysis
Linkage analysis was performed by use of parametric
methods of likelihood maximization—namely, classical
LOD-score analysis. Two-point linkage analysis was
conducted on a personal computer using version 5.2 of
the LINKAGE program (Ott 1991). Multipoint linkage
analysis was conducted on a VAX computer using FAST-
LINK. Autosomal-dominant inheritance was assumed,
and penetrance was set conservatively at 95%. The allele
frequencies for the disease and for the normal alleles
were assumed to be .0001 and .9999, respectively. The
allele frequencies for the microsatellite markers were ar-
bitrarily set equal to 1/n, where n is the number of alleles
observed.
Results
Clinical Findings
This family consists of 47 members spanning five gen-
erations (fig. 1). Of these individuals, 40 were living and
available for blood collection and clinical evaluation. All
30 of the living members who were at risk of having
inherited the disease-associated allele were thoroughly
investigated as outlined in the Subjects and Methods
section. A total of 22 subjects underwent RV endomy-
ocardial biopsy and histological examination. Several
complementary tests were performed in each at-risk in-
dividual because of the well-documented difficulties in
making a diagnosis of this disease. The diagnostic cat-
egory for each individual was based on the criteria es-
tablished by the ESC/IFSC, which proposed that two
major, one major and two minor, or four minor features
be present. By definition, all affected individuals satisfied
the major criterion of a positive family history.
Of the family members examined, 10 were diagnosed
as affected with ARVD. One of these individuals (IV:13)
later died of an unrelated malignancy. In addition, two
individuals (IV:14 and IV:17) who had died suddenly
were confirmed, on autopsy, to have been affected. The
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Figure 1 Pedigree of ARVD family studied. Circles denote females, squares denote males, blackened symbols denote affected individuals;
a slash through a symbol indicates that the individual is deceased, and a question mark (?) within a symbol indicates that the individual was
classified as indeterminate for purposes of linkage analysis.
remaining family members were classified as normal.
The diagnostic features of all living and deceased af-
fected individuals are summarized in table 1. All affected
individuals had significant cardiac tissue abnormalities
including fibro-fatty replacement, which, coupled with
the positive family history, were sufficient to allow a
positive diagnosis of ARVD. The histological abnor-
malities detected in the living affected individuals in-
cluded varying proportions of fibro-fatty replacement,
myocardial degeneration, myocyte hypertrophy, and mi-
tochondrial abnormalities in the right ventricle. In ad-
dition, 6 of the 10 living individuals had segmental or
global dysfunction of the right ventricle, in the presence
of normal function of the left ventricle, and 6 also had
suggestive electrophysiological (EP) findings. Thus, most
living affected individuals demonstrated findings in ex-
cess of the minimum required to make a positive diag-
nosis. In the two deceased patients, autopsies showed
transmural fibro-fatty replacement of the RV myocar-
dium, in the absence of valvular, coronary, or pericardial
disease or other known cardiac or noncardiac causes of
death (fig. 2).
Only 3 of the 10 living individuals reported any overt
clinical symptoms. One 5-year-old patient (V:4) had a
questionable history of syncopal episodes, and two
adults (III:8 and IV:10) complained of dyspnea. Nev-
ertheless, all individuals displayed abnormalities on non-
invasive and invasive testing. The average (SD) age at
the time of diagnosis was years. Six of the in-21 17
dividuals confirmed to have ARVD on endomyocardial
biopsy were age !10 years, with the youngest being only
2 years old. In addition, two patients (IV:8 and IV:10)
at an age similar to the age at death of patients who
had suddenly died exhibited inducible ventricular fib-
rillation during programmed EP stimulation. It seems
that this family is characterized by early subclinical
manifestations of ARVD in childhood that progress to
life-threatening EP disturbances and sudden death in
adulthood.
The pedigree indicates autosomal-dominant inheri-
tance with high penetrance (fig. 1). There were 12 af-
fected individuals (10 living and 2 dead), 8 of whom
were male. A striking clinical feature of ARVD in this
family is its early onset and high incidence of sudden
death.
Genetic Linkage Analysis
Forty family members were first genotyped with the
microsatellite markers appropriate for the knownARVD
loci, including 14q23, 1q42, 14q12, 2q32, and 3p23.
All of these loci were excluded for this family, on the
basis of a LOD score !2. Subsequently, a complete
genome scan was conducted by use of the highly infor-
mative markers selected by Applied Biosystems as an
initial mapping scan, together with additional markers
from the Ge´ne´thon map, to clarify some uninformative
markers. A significant positive LOD score (13) was ob-
tained with the marker D10S191 on the short arm of
chromosome 10. No positive LOD scores 11.5 were seen
for any of the other markers analyzed. A total of 20
additional markers surrounding D10S191 that were se-
lected from the Ge´ne´thon map were genotyped. A max-
imum two-point LOD score of 3.92 was achieved with
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Table 1
Clinical Features of Affected Members with Familial ARVD
PATIENT
AGE AT
DIAGNOSIS
(years) SEX
CLINICAL
PRESENTATION
ECG AND EPS
ABNORMALITIESa
RV ABNORMALITIES
ON IMAGING STUDIESb
PATHOLOGICAL FIND-
INGS ON ENDOMY-
OCARDIAL BIOPSY OR
AUTOPSY
NO. OF POSI-
TIVE DIAGNOS-
TIC CRITERIA
Major Minor
III:8 58 F Dyspnea ST elevation in
RPL
Fibro-fatty
replacement
2
IV:17 34 M Sudden death Transmural fibro-fatty
replacement on
autopsy
2
IV:8 36 M Asymptomatic Incomplete
RBBB, PACs,
PVCs, induci-
ble VF
Global dilatation and
hypokinesis of RV,
fatty infiltration of
RV-free wall on
MRI
Fibro-fatty
replacement
3 1
IV:10 35 M Dyspnea Complex PVCs,
nonsustained
VT, inducible
VF
RV dilatation Interstitial fibrosis 3 1
IV:13 33 F Asymptomatic Focal fibro-fatty
replacement
2
IV:14 29 M Sudden death Transmural fibro-fatty
replacement on au-
topsy
2
V:1 10 M Asymptomatic PACs, PVCs with
LBBB pattern
Dyskinesis to akinesis
and dilatation of in-
fundibulum, apical
aneurysm
Fibro-fatty
replacement
3 1
V:2 7 M Asymptomatic PACs and PVCs,
atrial flutter,
and PVCs dur-
ing EPS
Dyskinesis and dilata-
tion of infundibu-
lum
Fibro-fatty
replacement
2 2
V:3 5 M Asymptomatic RVOT dilatation,
sluggish RV apex
Fibro-fatty
replacement
2 1
V:4 5 F Syncope RV (especially RVOT)
dyskinesis and dila-
tation, marked RV
trabeculization
Interstitial fibrosis,
myofilament loss
and disarray, mito-
chondrial
abnormalities
2 1
V:5 5 F Asymptomatic Rare PVCs Mild apical
hypokinesis
Fibro-fatty replace-
ment, mitochondrial
abnormalities
2 1
V:6 2 M Asymptomatic Fibro-fatty replace-
ment, mitochondrial
abnormalities
2
a EPS = EP study; RPL = right precordial leads; RBBB = right bundle branch block; PACs = premature atrial complexes; PVCs = premature
ventricular complexes; VT = ventricular tachycardia (monomorphic); VF = ventricular fibrillation; LBBB = left bundle branch block.
b Echocardiogram, angiogram, and magnetic-resonance imaging (MRI).
marker D10S1664, at a recombination fraction (v) of 0
(table 2). Haplotype analysis of the family members,
which was based on the principle of minimal recombi-
nation, identified a chromosomal region of 10.6 cM,
flanked by markers D10S547 and D10S1653, on the
basis of the sex-averaged distance on the Ge´ne´thon map
(fig. 3) This haplotype was shared by all the affected but
none of the normal individuals. Multipoint linkage anal-
ysis was conducted but added no new information with
respect to location.
Discussion
A large white kindred residing in North America was
identified with ARVD segregating as an autosomal-dom-
inant trait. Our family has an Anglo-Saxon origin with
no known Italian background. By use of genetic linkage
analysis, a novel locus was identified on the short arm
of chromosome 10 (10p12-14). The chromosomal re-
gion between the flanking markers genetically linked to
the disease spans ∼10.6 cM. Studies to isolate the gene
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Table 2
Two-Point LOD Scores with Respect to ARVD in Family Studied
MARKER
TWO-POINT LOD SCORE AT v =
.0 .01 .05 .1 .2 .3 .4
D10S591 3.19 .78 .20 .55 .70 .58 .33
D10S1649 1.06 .97 1.48 1.53 1.31 .93 .48
D10S547 2.84 .67 1.19 1.27 1.10 .78 .40
D10S1707 3.34 3.29 3.09 2.82 2.24 1.58 .83
D10S1664 3.92 3.86 3.61 3.28 2.58 1.80 .93
D10S191 3.64 3.58 3.36 3.07 2.44 1.73 .91
D10S1653 2.76 2.72 2.56 2.34 1.86 1.32 .69
D10S548 3.04 2.99 2.80 2.54 1.99 1.38 .70
Figure 2 Endomyocardial biopsy of the right ventricle from one affected family member, stained with Masson trichrome; magnification
#400. Massive replacement of myocytes with adipose tissue (white) and fibrous tissue (blue) is characteristic of ARVD.
by simultaneous examination of candidate genes and
recruitment of additional family members for possible
recombinants, in an attempt to decrease the region, in
preparation for positional cloning, are ongoing. The dis-
ease in this family is distinguished by its early onset and
complete penetrance. The children with the disease hap-
lotype developed pathological abnormalities and/or a
clinical phenotype at age !10 years, with the youngest
being only 2 years old. Characteristically, ARVD has
been described as an autosomal-dominant disease with
reduced penetrance. The high penetrance and early onset
(age !10 years) of the disease observed in this family
appears to be unusual. The disease due to the gene
mapped to 3p23, the locus in another North American
family, had an incomplete penetrance of 67%, and the
age at diagnosis averaged 43 years (Ahmad et al. 1998).
Only a few early-onset cases have been reported in the
literature (Dungan et al. 1981; Pawal et al. 1994). Some
of the cases previously reported in children were actually
Uhl anomaly, which is now recognized to be a different
disease entity (Bharati et al. 1978; Vecht et al. 1979).
Therefore, the present locus at 10p12-14 appears to con-
tain a gene mutation that is responsible for a more ma-
lignant form of ARVD than that described for previous
loci. However, it is difficult to make comparisons, since
this possibility also relates to how early and how com-
plete the phenotype analysis was performed by other
investigators.
ARVD has only recently evolved into a recognizable
diagnostic entity. It is also thought to be distinct from
Uhl anomaly and RV outflow tract (RVOT [MIM
192605]) tachycardia (Marcus 1997). These diseases
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also occur in the right ventricle and have similar pa-
thology—namely, adipose and fibrous infiltrates (Basso
et al. 1996). RVOT tachycardia primarily occurs in the
outflow tract of the right ventricle and presents as a
ventricular tachycardia. The distinguishing features of
RVOT tachycardia are considered to be lack of family
history and a benign outcome. The arrhythmias usually
respond to beta blockers or calcium-channel blockers,
as opposed to the more resistant ARVD. Uhl anomaly
is a rare, lethal condition developed during infancy or
early childhood. It leads to congestive cardiac failure and
death after a few weeks or months. Pathologically, it
shows the striking pattern of a huge and transparent
right-ventricle free wall. This is thought to be the result
of apposition of the endocardium and epicardium with
some fatty tissue but without intervening myocardium.
Thus, Uhl anomaly is now recognized as a separate en-
tity, and, furthermore, there is no evidence that it is a
familial disease (Marcus 1997; Fontaine et al. 1998).
The study showing that ARVD accounts for 17% of
sudden death in young people in the United States was
performed retrospectively on postmortem cardiac tissue
(Shen et al. 1995). The true incidence and prevalence of
the disease in North America remains to be determined.
This is only the second locus to be identified as being
responsible for ARVD in a North American family (Ah-
mad et al. 1998). It is well recognized that ARVD is a
disease with highly variable clinical manifestations, and
the genetic defects exhibit locus heterogeneity. The phe-
notypic expression of the disease is extremely variable
and vague even within the same family (Nava et al.
1987). Some patients have a normal life expectancy,with
the diagnosis being made only postmortem. In contrast,
sudden death may occur as a first presentation during
the 2d or 3d decade (Fontaine et al. 1999). Only a small
percentage (15%–20%) of patients experience symp-
toms, and these are often nonspecific—for example, pal-
pitations, tachycardia, or syncope—with the majority of
patients, even those who undergo sudden death, re-
maining asymptomatic (Marcus et al. 1982; Fontaine et
al. 1999). Given the tremendous difficulty in diagnosis
of ARVD, identification of the responsible genes and
their mutations will represent a significant diagnostic
breakthrough. The treatment employed to prevent sud-
den death in ARVD is expensive—namely, an in-dwelling
automatic defibrillator. This device has been shown to
prevent sudden death due to other causes and to be
relatively safe compared with antiarrhythmic drugs.
Identification of mutations associated with a high inci-
dence of sudden death would significantly improve our
management of sudden death in this disease and would
provide a rational basis for selection of those at risk of
sudden death as possible candidates for automatic
defibrillators.
An intriguing aspect of the cardiac defect associated
with ARVD is its location in the right ventricle, with
essentially complete sparing of the septum (Marcus et
al. 1982). In contrast, other cardiomyopathies, such as
familial dilated cardiomyopathy (FDCM [MIM
601494]) and familial hypertrophic cardiomyopathy
(FHCM [MIM 192600]), affect primarily the left ven-
tricle (Marian and Roberts 1995). The mutant proteins
responsible for the defects in FDCM or FHCM are pre-
sent in similar abundance in the right and left ventricles.
Presumably, the high pressure in the left ventricle pre-
disposes to development of the phenotype. Because the
right ventricle is a low-pressure system, the physiological
factors predisposing to the involvement of the right over
the left ventricle are less obvious. However, it is possible
that the defective gene is preferentially expressed in the
right ventricle. For example, the gene HAND2 (d-
HAND), which is known to be essential for the normal
development of the right ventricle, is expressed only in
the right ventricle. However, the chromosome location
of HAND2 has not yet been mapped. To date, no as-
sociation of the HAND2 gene and human cardiac dis-
ease has been found (Srivastava et al. 1997). It will be
exciting to clarify whether the right ventricle is affected
because of a chamber-specific stimulus, differential gene
expression, or a combination of both. It has been pos-
tulated that the search for the genes responsible for car-
diac development will be accelerated by genes identified
to be responsible for cardiac diseases. Convergence of
the two fields could provide a unified scheme not only
for cardiac development and differentiation but also for
the adult cardiac-growth response to injury. Genes as-
sociated with apoptosis are speculated to be good can-
didate genes, because apoptosis has been documented in
the myocardium in ARVD (Mallat et al. 1996; Valente
et al. 1998). Among the genes mapped (Human Gene
Map) to the chromosome 10p12-14 locus are vimentin,
the macrophage mannose receptor–precursor gene, the
RSU-1/RSP-1 gene, and KIAA0019. Of these, vimentin
seems to be the most attractive candidate gene for car-
diomyopathy. Vimentin is a cytoskeletal protein, and
two of the genes so far identified to be responsible for
dilated cardiomyopathy of the left ventricle are actin and
desmin (Olson et al. 1998; Li et al. 1999). Furthermore,
vimentin is known to form a framework around lipid
granules and is said to be involved with adipogenesis
(Franke et al. 1987). It has been shown that mice ov-
erexpressing vimentin exhibit cataract formation (Ca-
petanaki et al. 1989). Interestingly, a familial case of
ARVD with anterior polar cataracts has been reported
recently (Frances et al. 1997). Thus, vimentin warrants
further study in this family, despite its ubiquitous
expression.
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